IQVIA: 80% of our trial sites are ‘inaccessible’ due to pandemic, eyes Q4 for turnaround

As IQVIA released its first-quarter financials Tuesday morning, the CRO-analytics firm outlined just how hard its R&D business had been hit by the COVID-19 pandemic.

IQVIA: 80% of our trial sites are ‘inaccessible’ due to pandemic, eyes Q4 for turnaround
As IQVIA released its first-quarter financials Tuesday morning, the CRO-analytics firm outlined just how hard its R&D business had been hit by the COVID-19 pandemic.